Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Portola Pharmaceuticals: CMS proposes extending NTAP for Andexxa » 08:11
05/14/20
05/14
08:11
05/14/20
08:11
PTLA

Portola Pharmaceuticals

$17.80 /

-0.005 (-0.03%)

Portola Pharmaceuticals…

Portola Pharmaceuticals announced that the U.S. Centers for Medicare & Medicaid Services has proposed extending the New Technology Add-on Payment for Andexxa [coagulation factor Xa through federal fiscal year 2021, for eligible Medicare beneficiaries treated in the inpatient hospital setting. Andexxa, first approved for use in the United States in May 2018, received its NTAP designation effective October 1, 2018.

ShowHide Related Items >><<
PTLA Portola Pharmaceuticals
$17.80 /

-0.005 (-0.03%)

PTLA Portola Pharmaceuticals
$17.80 /

-0.005 (-0.03%)

05/07/20 Stifel
Portola deal highlights value of PhaseBio's PB2452, says Stifel
05/06/20 B. Riley FBR
B. Riley boosts CytoSorbents target, says Portola deal highlights value
05/05/20 Citi
Portola Pharmaceuticals downgraded to Neutral from Buy at Citi
05/05/20 Jefferies
Jefferies sees Portola acquisition as neutral for Alexion
PTLA Portola Pharmaceuticals
$17.80 /

-0.005 (-0.03%)

PTLA Portola Pharmaceuticals
$17.80 /

-0.005 (-0.03%)

PTLA Portola Pharmaceuticals
$17.80 /

-0.005 (-0.03%)

Recommendations
Portola deal highlights value of PhaseBio's PB2452, says Stifel » 08:32
05/07/20
05/07
08:32
05/07/20
08:32
PHAS

PhaseBio

$4.85 /

+0.19 (+4.08%)

, PTLA

Portola Pharmaceuticals

$17.79 /

-0.04 (-0.22%)

As previously reported,…

As previously reported, on May 5 Stifel analyst Adam Walsh reiterated a Buy rating and $14 price target on PhaseBio Pharmaceuticals (PHAS), saying that while he acknowledges the "obvious" differences between Portola's (PTLA) Andexxa and PhasBio's PB2452, he believes Alexion's (ALXN) acquisition of Portola largely for Andexxa highlights the value of PB2452. Walsh said that while Andexxa is a factor Xa reversal agent used to prevent serious bleeding in patients on factor Xa inhibitors, PB2452 is a "first-in-class" reversal agent designed for the antiplatelet drug ticagrelor. The analyst added that he thinks the Portola deal should bring attention to PhaseBio's currently "underappreciated" lead asset and the potential for value creation it holds.

ShowHide Related Items >><<
PHAS PhaseBio
$4.85 /

+0.19 (+4.08%)

04/06/20 Citi
PhaseBio price target lowered to $11 from $25 at Citi
01/27/20 William Blair
PhaseBio could see increase to PB2452 addressable market, says William Blair
01/16/20 Stifel
PhaseBio acquisition of PB6440 an 'excellent' strategic move, says Stifel
PTLA Portola Pharmaceuticals
$17.79 /

-0.04 (-0.22%)

05/06/20 B. Riley FBR
B. Riley boosts CytoSorbents target, says Portola deal highlights value
05/05/20 Citi
Portola Pharmaceuticals downgraded to Neutral from Buy at Citi
05/05/20 Jefferies
Jefferies sees Portola acquisition as neutral for Alexion
Recommendations
B. Riley boosts CytoSorbents target, says Portola deal highlights value » 09:06
05/06/20
05/06
09:06
05/06/20
09:06
CTSO

CytoSorbents

$9.33 /

-0.03 (-0.32%)

, PTLA

Portola Pharmaceuticals

$17.83 /

+10.07 (+129.77%)

B. Riley FBR analyst…

B. Riley FBR analyst Andrew D'Silva raised the firm's price target on CytoSorbents (CSTO) to $16 from $12 and reiterates a Buy rating on the shares. The analyst believes physician awareness of the various indications that CytoSorb can treat has "materially increased and provides a significant tailwind on the other side of COVID-19." Further, yesterday's acquisition of Portola Pharmaceuticals (PTLA) highlights CytoSorbents' valuation potential, D'Silva tells investors in a research note. Portola's lead product, Andexxa is a factor Xa inhibitor reversal agent and is approved to reverse anticoagulant effects of factor Xa inhibitors rivaroxaban and apixaban. Recall, CytoSorbents recently obtained a CE Mark label expansion for CytoSorb to now include the removal of AstraZeneca's ticagrelor, a commonly used anti-platelet, during cardiopulmonary bypass, and was granted breakthrough designation by the FDA just last month, the analyst points out. He believes CytoSorb has several competitive advantages, as it hasn't been shown to result in serious adverse events.

ShowHide Related Items >><<
CTSO CytoSorbents
$9.33 /

-0.03 (-0.32%)

03/25/20 Dawson James
CytoSorbents being used for COVID-19 in Italy, China, says Dawson James
01/08/20 B. Riley FBR
B. Riley FBR highlights six Specialty Pharma stocks for 2020
10/21/19 B. Riley FBR
B. Riley FBR an 'aggressive' buyer of CytoSorbents after 31% selloff
PTLA Portola Pharmaceuticals
$17.83 /

+10.07 (+129.77%)

05/05/20 Citi
Portola Pharmaceuticals downgraded to Neutral from Buy at Citi
05/05/20 Jefferies
Jefferies sees Portola acquisition as neutral for Alexion
05/05/20 Piper Sandler
Alexion's management deserves benefit of the doubt, says Piper Sandler
On The Fly
Fly Intel: Wall Street's top stories for Tuesday » 17:05
05/05/20
05/05
17:05
05/05/20
17:05
PFE

Pfizer

$38.50 /

+0.87 (+2.31%)

, BNTX

BioNTech

$49.97 /

+4.41 (+9.68%)

, LB

L Brands

$11.63 /

-0.42 (-3.49%)

, W

Wayfair

$166.18 /

+32.04 (+23.89%)

, HTZ

Hertz

$3.01 /

-0.585 (-16.30%)

, ALXN

Alexion

$98.25 /

-5.64 (-5.43%)

, PTLA

Portola Pharmaceuticals

$17.83 /

+10.07 (+129.77%)

, UBER

Uber

$28.07 /

+0.66 (+2.41%)

, LYFT

Lyft

$26.68 /

-0.35 (-1.29%)

, AKBA

Akebia

$11.87 /

+3.2 (+36.91%)

, CHGG

Chegg

$57.95 /

+14.06 (+32.03%)

, TREX

Trex Company

$109.20 /

+8.94 (+8.92%)

, NCLH

Norwegian Cruise Line

$11.18 /

-3.25 (-22.53%)

, ITRI

Itron

$56.72 /

-10.98 (-16.22%)

, UNM

Unum Group

$15.20 /

-1.8 (-10.59%)

The major averages were…

Open Full Text

ShowHide Related Items >><<
PFE Pfizer
$38.50 /

+0.87 (+2.31%)

04/29/20 Piper Sandler
Piper backs Overweight on Opko as BioReference starts COVID-19 antibody testing
04/28/20 SVB Leerink
SVB Leerink bullish on Zentalis, initiates with an Outperform
04/28/20 BofA
BioNTech downgraded to Neutral from Buy at BofA
04/03/20 Canaccord
BioNTech price target raised to $60 from $22 at Canaccord
BNTX BioNTech
$49.97 /

+4.41 (+9.68%)

04/28/20 BofA
BioNTech downgraded to Neutral from Buy at BofA
04/13/20 H.C. Wainwright
BioNTech price target raised to $48 from $30 at H.C. Wainwright
LB L Brands
$11.63 /

-0.42 (-3.49%)

05/05/20
Fly Intel: Top five analyst upgrades
05/05/20 B. Riley FBR
B. Riley FBR remains buyer of L Brands with $23 price target
05/05/20 Deutsche Bank
L Brands price target lowered to $16 from $24 at Deutsche Bank
05/05/20 BMO Capital
BMO upgrades L Brands after Sycamore deal ends, sees 50%-70% upside
W Wayfair
$166.18 /

+32.04 (+23.89%)

05/06/20 DA Davidson
Wayfair price target raised to $100 from $45 at DA Davidson
05/06/20 SunTrust
Wayfair price target raised to $163 from $110 at SunTrust
05/06/20 Oppenheimer
Wayfair price target raised to $200 from $160 at Oppenheimer
05/06/20 Credit Suisse
Wayfair price target raised to $198 from $135 at Credit Suisse
HTZ Hertz
$3.01 /

-0.585 (-16.30%)

05/05/20 Morgan Stanley
2020 may not be quite as bad as feared for used cars, says Morgan Stanley
04/27/20
Fly Intel: Top five analyst downgrades
04/27/20 Barclays
Barclays downgrades Hertz to Underweight on risk of capital call
04/27/20 Barclays
Hertz downgraded to Underweight from Equal Weight at Barclays
ALXN Alexion
$98.25 /

-5.64 (-5.43%)

05/05/20 Jefferies
Jefferies sees Portola acquisition as neutral for Alexion
05/05/20 Piper Sandler
Alexion's management deserves benefit of the doubt, says Piper Sandler
05/05/20 William Blair
Portola downgraded to Market Perform from Outperform at William Blair
PTLA Portola Pharmaceuticals
$17.83 /

+10.07 (+129.77%)

05/05/20 Citi
Portola Pharmaceuticals downgraded to Neutral from Buy at Citi
UBER Uber
$28.07 /

+0.66 (+2.41%)

05/01/20 Citi
Lyft coverage resumed with a Buy at Citi
04/28/20 KeyBanc
KeyBanc says channel work points to Shake Shack reopening ordering system
04/21/20 Guggenheim
Guggenheim raises two auto parts retailers, cuts one supplier in sector shake-up
04/21/20 Argus
Lyft initiated with a Buy at Argus
LYFT Lyft
$26.68 /

-0.35 (-1.29%)

05/04/20 SunTrust
Lyft price target lowered to $45 from $74 at SunTrust
05/04/20 Credit Suisse
Lyft price target lowered to $75 from $96 at Credit Suisse
05/01/20
Fly Intel: Top five analyst initiations
AKBA Akebia
$11.87 /

+3.2 (+36.91%)

05/05/20 Piper Sandler
Piper Sandler remains a buyer of Akebia following Phase 3 INNO2VATE data
05/05/20 Piper Sandler
Piper says efficacy, safety of FibroGen, Akebia drugs 'quite similar' in DD-CKD
05/05/20 Piper Sandler
Piper sees Akebia shares having 'nice follow through' on pre-market upside
05/05/20 RBC Capital
Akebia could trade $5 to $8 higher on INNO2VATE data, says RBC Capital
CHGG Chegg
$57.95 /

+14.06 (+32.03%)

05/05/20 Barrington
Chegg price target raised to $60 from $50 at Barrington
05/05/20 Craig-Hallum
Chegg price target raised to $65 from $55 at Craig-Hallum
05/05/20 Northland
Chegg price target raised to $60 from $44 at Northland
TREX Trex Company
$109.20 /

+8.94 (+8.92%)

05/05/20 SunTrust
Trex Company price target raised to $99 from $90 at SunTrust
05/05/20 Deutsche Bank
Trex Company price target raised to $88 from $79 at Deutsche Bank
04/30/20
Fly Intel: Top five analyst initiations
04/29/20 Baird
Trex Company initiated with a Neutral at Baird
NCLH Norwegian Cruise Line
$11.18 /

-3.25 (-22.53%)

05/05/20 Goldman Sachs
Goldman says capital raise gives Norwegian runway to endure slow recovery
04/23/20 Stifel
Stifel calls Royal best positioned cruise operator, ups target to $48
04/20/20 JPMorgan
Norwegian Cruise Line price target lowered to $26 from $60 at JPMorgan
04/08/20 Nomura Instinet
Norwegian Cruise Line price target lowered to $23 from $37 at Nomura Instinet
ITRI Itron
$56.72 /

-10.98 (-16.22%)

05/05/20 Cowen
Itron price target lowered to $78 from $88.50 at Cowen
03/19/20 Argus
Itron downgraded to Hold from Buy at Argus
03/19/20 Argus
Itron downgraded to Hold from Buy at Argus
02/25/20 JMP Securities
Itron price target raised to $95 from $90 at JMP Securities
UNM Unum Group
$15.20 /

-1.8 (-10.59%)

05/06/20 SunTrust
Unum Group price target lowered to $30 from $44 at SunTrust
05/06/20 RBC Capital
Unum Group price target lowered to $22 from $26 at RBC Capital
03/20/20 RBC Capital
Unum Group price target lowered to $26 from $33 at RBC Capital
03/20/20 RBC Capital
RBC Capital sees some time before Life Insurance returns to 'normal'
  • 06
    May
Downgrade
Portola Pharmaceuticals downgraded to Neutral from Buy at Citi » 13:57
05/05/20
05/05
13:57
05/05/20
13:57
PTLA

Portola Pharmaceuticals

$17.83 /

+10.07 (+129.77%)

Citi downgraded Portola…

Citi downgraded Portola Pharmaceuticals (PTLA) to Neutral from Buy after the company agreed to be acquired by Alexion (AXLN).

ShowHide Related Items >><<
PTLA Portola Pharmaceuticals
$17.83 /

+10.07 (+129.77%)

05/05/20 Jefferies
Jefferies sees Portola acquisition as neutral for Alexion
05/05/20 Piper Sandler
Alexion's management deserves benefit of the doubt, says Piper Sandler
05/05/20 William Blair
Portola downgraded to Market Perform from Outperform at William Blair
04/23/20
Fly Intel: Top five analyst initiations
Recommendations
Jefferies sees Portola acquisition as neutral for Alexion » 13:11
05/05/20
05/05
13:11
05/05/20
13:11
ALXN

Alexion

$98.47 /

-5.42 (-5.22%)

, PTLA

Portola Pharmaceuticals

$17.88 /

+10.12 (+130.41%)

Jefferies analyst Eun…

Jefferies analyst Eun Yang lowered the firm's price target on Alexion Pharmaceuticals (ALXN) to $112 from $115 and keeps a Buy rating on the shares. The stock in afternoon trading is down 5% to $98.23. Compared to its acquisition five years ago of Synageva for $8.4B, Alexion's purchase of Portola Pharmaceuticals (PTLA) at $1.4B for recently launched Andexxa potential "seems reasonable," albeit not exciting and "debatable commercial potential," Yang tells investors in a research note. On the analyst's assumed $500M in Andexxa sales in 2026, she views the deal as Neutral to Alexion.

ShowHide Related Items >><<
ALXN Alexion
$98.47 /

-5.42 (-5.22%)

05/05/20 Piper Sandler
Alexion's management deserves benefit of the doubt, says Piper Sandler
05/05/20 William Blair
Portola downgraded to Market Perform from Outperform at William Blair
04/27/20 Cantor Fitzgerald
Alexion initiated with a Neutral at Cantor Fitzgerald
04/21/20 Baird
Alexion thesis unchanged following Ultomiris advance, says Baird
PTLA Portola Pharmaceuticals
$17.88 /

+10.12 (+130.41%)

04/23/20
Fly Intel: Top five analyst initiations
04/23/20 RBC Capital
Portola Pharmaceuticals initiated with an Outperform at RBC Capital
Recommendations
Alexion's management deserves benefit of the doubt, says Piper Sandler » 13:00
05/05/20
05/05
13:00
05/05/20
13:00
ALXN

Alexion

$98.50 /

-5.39 (-5.19%)

, PTLA

Portola Pharmaceuticals

$17.86 /

+10.095 (+130.09%)

Piper Sandler analyst…

Piper Sandler analyst Christopher Raymond retained an Overweight rating on shares of Alexion Pharmaceuticals (ALXN) despite the "lukewarm" reception to the announced acquisition of Portola (PTLA). In a research note to investors, Raymond says he thinks Alexion's management team deserves the benefit of the doubt, and despite many questions on the part of investors, thinks Alexion can derive commercial synergies between Andexxa and Soliris/Ultomiris aHUS and NMO call points.

ShowHide Related Items >><<
ALXN Alexion
$98.50 /

-5.39 (-5.19%)

04/27/20 Cantor Fitzgerald
Alexion initiated with a Neutral at Cantor Fitzgerald
04/21/20 Baird
Alexion thesis unchanged following Ultomiris advance, says Baird
04/20/20 Morgan Stanley
Court claim construction largely favors Chugai over Alexion, says Morgan Stanley
PTLA Portola Pharmaceuticals
$17.86 /

+10.095 (+130.09%)

05/05/20 William Blair
Portola downgraded to Market Perform from Outperform at William Blair
04/23/20
Fly Intel: Top five analyst initiations
04/23/20 RBC Capital
Portola Pharmaceuticals initiated with an Outperform at RBC Capital
01/10/20 Cowen
Portola Pharmaceuticals price target lowered to $35 from $45 at Cowen
On The Fly
Fly Intel: Wall Street's top stories at midday » 12:26
05/05/20
05/05
12:26
05/05/20
12:26
PFE

Pfizer

$38.73 /

+1.1 (+2.92%)

, BNTX

BioNTech

$48.65 /

+3.09 (+6.78%)

, LB

L Brands

$12.11 /

+0.06 (+0.50%)

, W

Wayfair

$166.61 /

+32.47 (+24.21%)

, HTZ

Hertz

$3.08 /

-0.51 (-14.21%)

, ALXN

Alexion

$98.95 /

-4.94 (-4.76%)

, PTLA

Portola Pharmaceuticals

$17.80 /

+10.04 (+129.38%)

, AKBA

Akebia

$11.66 /

+2.99 (+34.49%)

, CHGG

Chegg

$58.34 /

+14.45 (+32.92%)

, TREX

Trex Company

$109.00 /

+8.74 (+8.72%)

, NCLH

Norwegian Cruise Line

$11.62 /

-2.805 (-19.45%)

, ITRI

Itron

$54.82 /

-12.88 (-19.03%)

, UNM

Unum Group

$15.61 /

-1.39 (-8.18%)

The major averages are…

Open Full Text

ShowHide Related Items >><<
PFE Pfizer
$38.73 /

+1.1 (+2.92%)

04/29/20 Piper Sandler
Piper backs Overweight on Opko as BioReference starts COVID-19 antibody testing
04/28/20 SVB Leerink
SVB Leerink bullish on Zentalis, initiates with an Outperform
04/28/20 BofA
BioNTech downgraded to Neutral from Buy at BofA
04/03/20 Canaccord
BioNTech price target raised to $60 from $22 at Canaccord
BNTX BioNTech
$48.65 /

+3.09 (+6.78%)

04/28/20 BofA
BioNTech downgraded to Neutral from Buy at BofA
04/13/20 H.C. Wainwright
BioNTech price target raised to $48 from $30 at H.C. Wainwright
LB L Brands
$12.11 /

+0.06 (+0.50%)

05/05/20
Fly Intel: Top five analyst upgrades
05/05/20 B. Riley FBR
B. Riley FBR remains buyer of L Brands with $23 price target
05/05/20 Deutsche Bank
L Brands price target lowered to $16 from $24 at Deutsche Bank
05/05/20 BMO Capital
BMO upgrades L Brands after Sycamore deal ends, sees 50%-70% upside
W Wayfair
$166.61 /

+32.47 (+24.21%)

05/05/20 Piper Sandler
Wayfair price target raised to $220 from $140 at Piper Sandler
05/05/20 Loop Capital
Loop upgrades Wayfair to Hold, 'caught by surprise' by sales, cost controls
05/05/20 Loop Capital
Wayfair upgraded to Hold from Sell at Loop Capital
05/04/20 Credit Suisse
Wayfair price target raised to $135 from $110 at Credit Suisse
HTZ Hertz
$3.08 /

-0.51 (-14.21%)

04/27/20
Fly Intel: Top five analyst downgrades
04/27/20 Barclays
Barclays downgrades Hertz to Underweight on risk of capital call
04/27/20 Barclays
Hertz downgraded to Underweight from Equal Weight at Barclays
04/23/20 JPMorgan
JPMorgan sees rental cars as 'worst positioned,' cuts Hertz to Underweight
ALXN Alexion
$98.95 /

-4.94 (-4.76%)

05/05/20 William Blair
Portola downgraded to Market Perform from Outperform at William Blair
04/27/20 Cantor Fitzgerald
Alexion initiated with a Neutral at Cantor Fitzgerald
04/21/20 Baird
Alexion thesis unchanged following Ultomiris advance, says Baird
04/20/20 Morgan Stanley
Court claim construction largely favors Chugai over Alexion, says Morgan Stanley
PTLA Portola Pharmaceuticals
$17.80 /

+10.04 (+129.38%)

04/23/20
Fly Intel: Top five analyst initiations
04/23/20 RBC Capital
Portola Pharmaceuticals initiated with an Outperform at RBC Capital
01/10/20 Cowen
Portola Pharmaceuticals price target lowered to $35 from $45 at Cowen
AKBA Akebia
$11.66 /

+2.99 (+34.49%)

05/05/20 Piper Sandler
Piper says efficacy, safety of FibroGen, Akebia drugs 'quite similar' in DD-CKD
05/05/20 Piper Sandler
Piper sees Akebia shares having 'nice follow through' on pre-market upside
05/05/20 RBC Capital
Akebia could trade $5 to $8 higher on INNO2VATE data, says RBC Capital
03/10/20 Piper Sandler
Akebia should be bought despite another Auryxia miss, says Piper Sandler
CHGG Chegg
$58.34 /

+14.45 (+32.92%)

05/05/20 Barrington
Chegg price target raised to $60 from $50 at Barrington
05/05/20 Craig-Hallum
Chegg price target raised to $65 from $55 at Craig-Hallum
05/05/20 Northland
Chegg price target raised to $60 from $44 at Northland
TREX Trex Company
$109.00 /

+8.74 (+8.72%)

05/05/20 SunTrust
Trex Company price target raised to $99 from $90 at SunTrust
05/05/20 Deutsche Bank
Trex Company price target raised to $88 from $79 at Deutsche Bank
04/30/20
Fly Intel: Top five analyst initiations
04/29/20 Baird
Trex Company initiated with a Neutral at Baird
NCLH Norwegian Cruise Line
$11.62 /

-2.805 (-19.45%)

05/05/20 Goldman Sachs
Goldman says capital raise gives Norwegian runway to endure slow recovery
04/23/20 Stifel
Stifel calls Royal best positioned cruise operator, ups target to $48
04/20/20 JPMorgan
Norwegian Cruise Line price target lowered to $26 from $60 at JPMorgan
04/08/20 Nomura Instinet
Norwegian Cruise Line price target lowered to $23 from $37 at Nomura Instinet
ITRI Itron
$54.82 /

-12.88 (-19.03%)

05/05/20 Cowen
Itron price target lowered to $78 from $88.50 at Cowen
03/19/20 Argus
Itron downgraded to Hold from Buy at Argus
03/19/20 Argus
Itron downgraded to Hold from Buy at Argus
02/25/20 JMP Securities
Itron price target raised to $95 from $90 at JMP Securities
UNM Unum Group
$15.61 /

-1.39 (-8.18%)

03/20/20 RBC Capital
Unum Group price target lowered to $26 from $33 at RBC Capital
03/20/20 RBC Capital
RBC Capital sees some time before Life Insurance returns to 'normal'
03/11/20 Credit Suisse
Unum Group upgraded to Neutral from Underperform at Credit Suisse
01/02/20 JPMorgan
JPMorgan cautious on life insurance sector in 2020
  • 06
    May
Downgrade
Portola downgraded to Market Perform from Outperform at William Blair » 11:50
05/05/20
05/05
11:50
05/05/20
11:50
PTLA

Portola Pharmaceuticals

$17.80 /

+10.035 (+129.32%)

, ALXN

Alexion

$98.71 /

-5.18 (-4.99%)

William Blair analyst…

William Blair analyst Matt Phipps downgraded Portola Pharmaceuticals (PTLA) to Market Perform from Outperform after the company agreed to be acquired by Alexion (AXLN).

ShowHide Related Items >><<
PTLA Portola Pharmaceuticals
$17.80 /

+10.035 (+129.32%)

04/23/20
Fly Intel: Top five analyst initiations
04/23/20 RBC Capital
Portola Pharmaceuticals initiated with an Outperform at RBC Capital
01/10/20 Cowen
Portola Pharmaceuticals price target lowered to $35 from $45 at Cowen
01/10/20 Oppenheimer
Oppenheimer downgrades Portola on Andexxa headwinds, cuts target to $17
ALXN Alexion
$98.71 /

-5.18 (-4.99%)

04/27/20 Cantor Fitzgerald
Alexion initiated with a Neutral at Cantor Fitzgerald
04/21/20 Baird
Alexion thesis unchanged following Ultomiris advance, says Baird
04/20/20 Morgan Stanley
Court claim construction largely favors Chugai over Alexion, says Morgan Stanley
03/17/20 Oppenheimer
Alexion downgraded to Perform at Oppenheimer
Options
Unusually active option classes on open May 5th » 09:40
05/05/20
05/05
09:40
05/05/20
09:40
PTLA

Portola Pharmaceuticals

$7.76 /

+ (+0.00%)

, GNPX

Genprex

$2.34 /

+ (+0.00%)

, NRZ

New Residential

$6.05 /

+ (+0.00%)

, RSX

Market Vectors Russia ETF

$18.93 /

+ (+0.00%)

, SH

ProShares Short S&P500

$24.73 /

+ (+0.00%)

, PLUG

Plug Power

$4.07 /

+ (+0.00%)

, CCJ

Cameco

$10.88 /

+ (+0.00%)

, UNG

United States Natural Gas Fund

$13.77 /

+ (+0.00%)

, PFE

Pfizer

$37.63 /

+ (+0.00%)

, ATVI

Activision Blizzard

$66.68 /

+ (+0.00%)

Unusual total active…

Unusual total active option classes on open include: Portola Pharmaceuticals (PTLA), Genprex (GNPX), New Residential (NRZ), Market Vectors Russia (RSX), ProShares Short S&P 500 (SH), Plug Power (PLUG), Cameco (CCJ), U.S. Natural Gas Fund (UNG), Pfizer (PFE), and Activision Blizzard (ATVI).

ShowHide Related Items >><<
PTLA Portola Pharmaceuticals
$7.76 /

+ (+0.00%)

04/23/20
Fly Intel: Top five analyst initiations
04/23/20 RBC Capital
Portola Pharmaceuticals initiated with an Outperform at RBC Capital
01/10/20 Cowen
Portola Pharmaceuticals price target lowered to $35 from $45 at Cowen
01/10/20 Oppenheimer
Oppenheimer downgrades Portola on Andexxa headwinds, cuts target to $17
GNPX Genprex
$2.34 /

+ (+0.00%)

04/22/20 Alliance Global Partners
Genprex initiated with a Buy at Alliance Global Partners
NRZ New Residential
$6.05 /

+ (+0.00%)

04/08/20 B. Riley FBR
Cherry Hill Mortgage price target lowered to $9 from $15 at B. Riley FBR
04/06/20 Raymond James
Raymond James cuts estimates and targets for residential mortgage REITs
04/02/20 BTIG
New Residential price target lowered to $10.50 from $18 at BTIG
04/02/20 Argus
New Residential downgraded to Hold from Buy at Argus
RSX Market Vectors Russia ETF
$18.93 /

+ (+0.00%)

SH ProShares Short S&P500
$24.73 /

+ (+0.00%)

PLUG Plug Power
$4.07 /

+ (+0.00%)

04/24/20 Morgan Stanley
Federal support for renewables could come in summer, says Morgan Stanley
03/10/20 H.C. Wainwright
Plug Power price target raised to $6 from $4 at H.C. Wainwright
03/06/20 Oppenheimer
Plug Power price target raised to $6 from $3 at Oppenheimer
01/06/20 Roth Capital
Roth Capital expects more large size orders coming for Plug Power
CCJ Cameco
$10.88 /

+ (+0.00%)

05/04/20 TD Securities
Cameco upgraded to Buy from Hold at TD Securities
04/02/20 RBC Capital
RBC Capital maintains Sector Perform on Cameco
04/01/20 CIBC
Cameco upgraded to Outperformer from Neutral at CIBC
UNG United States Natural Gas Fund
$13.77 /

+ (+0.00%)

PFE Pfizer
$37.63 /

+ (+0.00%)

04/29/20 Piper Sandler
Piper backs Overweight on Opko as BioReference starts COVID-19 antibody testing
04/28/20 SVB Leerink
SVB Leerink bullish on Zentalis, initiates with an Outperform
04/28/20 BofA
BioNTech downgraded to Neutral from Buy at BofA
04/03/20 Canaccord
BioNTech price target raised to $60 from $22 at Canaccord
ATVI Activision Blizzard
$66.68 /

+ (+0.00%)

04/09/20 Jefferies
Zynga shares can top $8 amid stay at home environment, says Jefferies
04/08/20 Piper Sandler
Piper lays out winners and losers in survey of 5,200 teens
04/06/20 Wells Fargo
Activision Blizzard initiated with an Overweight at Wells Fargo
04/02/20 MKM Partners
Activision Blizzard upgraded to Buy from Neutral at MKM Partners

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.